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Introduction: Deep transcranial magnetic stimulation (dTMS) is a new form ofTMS allow-
ing safe stimulation of deep brain regions. The objective of this preliminary study was to
assess the role of dTMS maintenance sessions in protecting patients with bipolar disorder
(BD) or recurrent major depressive disorder (MDD) from developing depressive or manic
relapses in a 12-month follow-up period.
Methods: Twenty-four drug-resistant patients with a current depressive episode and a
diagnosis of MDD or BD have been enrolled in the study. All the participants underwent
daily dTMS sessions for 4 weeks. One group (maintenance – M group) received additional
maintenance dTMS sessions weekly or twice a week.
Results: After the first dTMS cycle, a significant reduction of Hamilton Depression Rat-
ing Scale (HDRS) scores was observed in all participants. Subsequently, the HDRS mean
scores did not significantly change over time in the M group, while it significantly increased
in the non-M-group after 6 and 12 months.
Discussion:This study confirms previous evidence of a positive therapeutic effect of dTMS
on depressive symptoms and suggests that, after recovery from acute episodes, mainte-
nance dTMS sessions may be helpful in maintaining euthymia in a 12-month follow-up
period.
Keywords: deep transcranial magnetic stimulation, bipolar disorder, neuropsychiatry, brain modulation, recurrent
major depressive disorder
INTRODUCTION
Repetitive transcranial magnetic stimulation (rTMS) is a non-
invasive technique used to treat drug-resistant depressive episodes
in major depressive disorder (MDD) (1) and bipolar disorder
(BD) (2), as well as a range of other neurological and psychiatric
conditions (3). rTMS therapy is administered through an electro-
magnetic coil placed above patient’s scalp; the coil sends magnetic
pulses to the brain and induces a modulation of the electrical
activity in the underlying cortex (3).
Neuroimaging studies have led to the imbalance hypothesis of
depression, which postulates prefrontal asymmetry with relative
hypoactivity in the left dorsolateral prefrontal cortex (DLPFC),
associated with a relative hyperactivity in the right DLPFC (4).
Consistently, patients with depression have been found to benefit
from excitatory high-frequency (more than 1 Hz) rTMS over the
left DLPFC and inhibitory low-frequency (<1 Hz) rTMS over the
right DLPFC (5).
There is evidence that clinical depression involves dysfunction
in integrated neural pathways linking cortical, subcortical, and
limbic sites and related cellular and molecular mediators (6); it is
supported that effective stimulation of this pathway would ben-
efit patients with depressive symptoms, but also that the regions
involved cannot be effectively stimulated utilizing standard rTMS
technology (7). For this reason, a new coil (H-coil) has been devel-
oped to allow safer stimulation of deeper brain regions [Deep
Transcranial Magnetic Stimulation (dTMS)] (8).
Several studies assessed the efficacy and safety of dTMS in MDD
[for review, see Ref. (9)], and one study assessed it in BD depres-
sion (10). Studies suggested a positive therapeutic effect of dTMS
in patients with depression when used as add-on to medications;
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however, in spite of obtaining encouraging results, no studies so
far investigated its long-term efficacy or the possible role of main-
tenance dTMS sessions in protecting patients from depressive or
manic relapses. We previously reported a 6-month improvement
of depression in a patient with rapid cycling BD and protection
from mood episodes of any polarity (11).
Given the above considerations, in this preliminary study, we
aimed to further assess the efficacy of daily add-on dTMS in reliev-
ing drug-resistant bipolar and recurrent unipolar depression, and
also to evaluate the role of dTMS maintenance sessions in protect-
ing patients from developing depressive or manic relapses during
a 12-month follow-up period.
MATERIALS AND METHODS
PATIENTS
The study was conducted at the Psychiatric Unit of the Sant’Andrea
University Hospital, Sapienza University, Rome, Italy, and at the
Neuropsychiatric Unit, Villa Rosa Hospital, Viterbo. Recruitment
was carried-out from October 2011 to April 2013; 24 consecutive
drug-resistant, right-handed patients (13 male, 11 female) with a
current DSM-IV-TR depressive episode were enrolled. All patients
were Caucasian. Eight had BD Type I (all from Rome), seven had
BD Type II (one from Viterbo, others from Rome), and nine had
MDD diagnosis (three patients from Viterbo, others from Rome).
Patients had no other psychiatric comorbidity. Diagnoses were
established through the Structured Clinical Interviews for DSM-
IV Axis I (SCID-I) and II (SCID-II); details are given in Table 1.
All patients gave written informed consent for participation in the
study and subsequent publication of results. The study received
the approval of the local ethical boards (human experimentation
ethics committee of Sapienza University, Rome, Italy, and Villa
Rosa, Viterbo).
Inclusion criteria were a current depressive episode and a diag-
nosis of BD or MDD; age 18–75 years; at least 5-year duration of
illness; failure to respond to at least three adequately dosed anti-
depressants from at least two distinct classes administered for at
least 2 months each; availability of reliable informants; wish to
participate in the study. Exclusion criteria were concomitant use
of substances (with the exception of nicotine, occasional alcohol,
and three or less daily cups of coffee or tea); specific contraindica-
tions to dTMS (history of seizures, pacemakers, or other electric
devices); axis I diagnosis other than MDD and BD; having received
dTMS in the past 12 months; left handedness. All patients were on
stable drug treatment from at least 1 month. Medication was left
unchanged and its details are given in Table 1.
A response of a depressive episode to treatment was defined as
an at least 50% drop of Hamilton Depression Rating Scale (HDRS)
scores from baseline, a remission was a HDRS score of 7 or less,
Table 1 | Participants’ clinical and sociodemographic characteristics.
Patients with dTMS
maintenance (N =12),
mean±SD
Patients without dTMS
maintenance, N=12,
mean±SD
Mann–Whitney
U -test
χ2 P
Age 47.70±8.90 48.50±14.26 59.5 0.478
Men, N (%) 6 (50) 5 (41.7) 0.682a
DSM-IV-TR diagnosis
BD I, N (%) 4 (33.3) 4 (33.3)
BD II, N (%) 4 (33.3) 3 (25)
MDD, N (%) 4 (33.3) 5 (41.7) 0.254 0.881
Duration of disease (years) 15.00±9.71 13.10±9.62 60.0 0.514
Drug treatment
Mood stabilizers, N (%) 9 (75) 7 (58.3) 0.386a
Benzodiazepines, N (%) 1 (8.3) 5 (41.7) 0.059a
Antidepressants, N (%) 5 (41.7) 7 (58.3) 0.414a
Two or more psychotropic medications, N (%) 3 (25) 4 (33) 0.653a
Clinical scales
Baseline HDRS 23.83±3.27 23.50±3.28 66.5 0.755
Post-dTMS cycle HDRS 9.83±1.27 9.92±2.35 71.5 0.977
HDRS at 6-month follow-up 9.33±2.23 13.75±5.53 34.5 0.028
HDRS at 12-month follow-up 12.92±5.78 16.17±7.11 55.5 0.347
Baseline YMRS 2.42±1.16 2.50±0.67 60.0 0.514
Post-dTMS cycle YMRS 2.17±0.58 2.75±0.97 48.0 0.178
YMRS at 6-month follow-up 2.33±0.89 2.83±1.12 56.5 0.378
YMRS at 12-month follow-up 2.66±1.16 3.08±0.52 57.5 0.410
aOne-way Fisher exact tests.
BD I, Bipolar Disorder Type I; BD II, Bipolar Disorder Type II; MDD, Major depressive disorder; HDRS, Hamilton Depression Rating Scale; YMRS, Young Mania Rating
Scale. Significant results in bold characters.
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while a relapse and recurrence were considered the emergence
of a fully symptomatic depressive episode after full remission or
recovery, respectively (12, 13).
CLINICAL MEASURES
Patients were assessed for mood disorder by trained clinicians
through the HDRS (14) and through the Young Mania Rating
Scale (YMRS) (15) at baseline, at the end of the first cycle of
dTMS treatment, after 6 and after 12 months from the end of the
first cycle of dTMS treatment.
The HDRS is a 21-item clinician-rated scale designed to assess
severity of depressive symptoms; single items are Likert, rang-
ing 0–4 (8 items) or 0–2 (9 items); 0–7 is normal, 8–13 is mild
depression, 14–18 moderate depression, 19–22 severe depression,
and ≥23 very severe depression; a score of ≤7 indicates remis-
sion of symptoms (13). The YMRS is an 11-item clinician-rated
scale designed to assess the severity of manic symptoms; 4 of the
YMRS items are rated on a 0–8 scale, with the remaining 5 items
being rated on a 0–4 scale; a score of ≤12 indicates no mania or
remission of symptoms (15).
DEEP TMS PROTOCOL
For dTMS sessions, we used Brainsway’s H1 coil deep TMS Sys-
tem (Brainsway, Har Hotzvim, Jerusalem, Israel). The H1 coil
is designed to elicit neuronal activation in medial and lateral
prefrontal regions, including the orbitofrontal cortex, with a pref-
erence for the left hemisphere (16). H1 coils were positioned
over patients’ scalp. The optimal spot on the scalp for stimula-
tion of the right abductor pollicis brevis muscle was located, and
the motor threshold established by delivering single stimulations
to the motor cortex. The motor threshold, defined as the low-
est stimulation intensity producing five motor evoked potentials
(MEPs) of at least 50µV in 5 of 10 stimulations, was measured by
gradually increasing stimulation intensity. The site of stimulation
was located 5.5 cm anterior to the point at which maximum stim-
ulation of the abductor pollicis brevis muscle was reached. dTMS
treatment was delivered by three expert, trained, certified physi-
cians (CR, VRF, SDP) in 20-min sessions. Each patient received 55
18-Hz trains per session at 120% of the measured motor thresh-
old, with 2-s duration each and 20 s inter-train intervals, for a
total of 1,980 pulses per session. The complete cycle of the dTMS
treatment consisted of 5 consecutive session days in a week for 4
consecutive weeks, for a total of 20 sessions amounting to 39,600
pulses for each patient. These parameters are the same as our
research team endorsed in treating clinically depressed patients
(17–19) and are recommended by the manufacturers.
The first complete cycle of the dTMS treatment consisted of 5
consecutive session days in a week for 4 consecutive weeks, for a
total of 20 sessions amounting to 39,600 pulses for each patient.
After the first dTMS cycle, patients were randomly assigned to
two groups, one receiving maintenance dTMS sessions (M), and
another, which returned to background pharmacotherapy with
no further dTMS sessions (non-maintenance group, NM). The M
group received 2 sessions per week during the first month after
the conclusion of the regular dTMS cycle and 1 weekly session
for the subsequent 2 months for a total of 16 sessions after the 20
regular dTMS sessions. Other measures related to the session, i.e.,
frequency, number of pulses and trains, stimulus duration, and
inter-train intervals were as in the regular sessions.
STATISTICAL ANALYSIS
All analyses were performed with SPSS 19.0 statistical package
for the social sciences (IBM, Armonk, NY, USA). The Mann–
Whitney U -test was used for the between-groups comparison
(M vs. NM patients); the non-parametric Wilcoxon Sign Test
was used for within-groups comparisons (pre-dTMS vs. post-
dTMS; post-dTMS vs. 6-month follow-up; post-dTMS vs. 12-
month follow-up). The use of the non-parametric tests was chosen
because none of the examined variables were normally distributed
(Shapiro–Wilk test, p< 0.05) in all considered conditions. Finally,
one-way Fisher exact tests and Chi-squared tests (χ2) for N ×N
contingency tables were used.
RESULTS
Drug treatment and other baseline patient characteristics are given
in Table 1. M and NM groups did not significantly differ for gender,
age, duration of disease, and drug treatment, as well as for baseline
and post-treatment HDRS and YMRS scores (Table 1). Compared
to NM patients, M patients scored lower on the HDRS at the 6-
month follow-up (13.75± 5.53 vs. 9.33± 2.23; p= 0.028); there
were no significant between-groups differences in HDRS mean
scores at the 12-month follow-up (Table 1). YMRS scores between
M and NM did not differ significantly at both 6- and 12-month
follow-up time-points (Table 1).
After the first dTMS treatment sessions, a significant reduc-
tion of HDRS scores was observed in both M (pre-dTMS
HDRS: 23.83± 3.27; post-dTMS HDRS: 9.83± 1.27; p= 0.002)
and NM groups (pre-dTMS HDRS: 23.50± 3.28; post-dTMS
HDRS: 9.92± 2.35; p= 0.002) (Table 2). However, while in M,
the HDRS mean scores did not significantly change at the 6- and
12-month follow-up (Table 2), a significant increase of HDRS
occurred in NM at the 6-month follow-up (post-dTMS HDRS:
Table 2 |Within-groups HDRS changes after dTMS, at the 6-month
follow-up, and at the 12-month follow-up.
Patients with
dTMS
maintenance,
mean±SD
P Patients
without dTMS
maintenance,
mean±SD
P
Baseline HDRS 23.83±3.27 23.50±3.28
Post-dTMS HDRS 9.83±1.27 9.92±2.35
Wilcoxon-Z Test −3.070 0.002 −3.083 0.002
Post-dTMS HDRS 9.83±1.27 9.92±2.35
HDRS at 6-month
follow-up
9.33±2.23 13.75±5.53
Wilcoxon-Z Test −0.770 0.441 −1.995 0.046
Post-dTMS HDRS 9.83±1.27 9.92±2.35
HDRS at 12-month
follow-up
12.92±5.78 16.17±7.11
Wilcoxon-Z Test −1.146 0.252 −2.050 0.040
Significant results in bold characters.
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9.92± 2.35; 6-month HDRS: 13.75± 5.53; p= 0.046), which were
further strengthened at the 12-month follow-up (post-dTMS
HDRS: 9.92± 2.35; 12-month HDRS: 16.17± 7.11; p= 0.040)
(Table 2).
DISCUSSION
Deep transcranial magnetic stimulation is a promising new treat-
ment for resistant depression, but it has still to gain a foothold in
current practice. Studies heretofore have shown its efficacy as add-
on and its safety, but the general impression is one of a fleeting
effect. The idea of maintenance sessions came from the practice of
electroconvulsive therapy. The only study in literature that envis-
aged maintenance was an open-label study and reported positive
results, provided that negative cognitive–emotional reactivation is
kept low (20). Our study confirmed previous evidence of a possible
positive therapeutic effect of H-coil dTMS on depressive symp-
toms in BD and MDD when added on ongoing treatment with
mood stabilizers and antidepressants. The significant decrease of
HDRS scores after the first dTMS cycle (Tables 1 and 2) pointed
to improvement of depression.
Our results also suggest that, after remission/recovery from an
acute episode, maintenance dTMS sessions may be helpful in pre-
venting depressive or manic relapses and maintaining euthymia in
a 12-month follow-up period. In fact, while the patients with no
continuation dTMS sessions showed a gradual significant increase
in HDRS scores after 6 and 12 months, the HDRS scores of patients
who underwent maintenance dTMS did not significantly change
over time (Table 2). In addition, patients who underwent mainte-
nance dTMS therapy scored significantly lower on the HDRS with
respect to patients randomized to receive no additional dTMS ses-
sions after 6 months (Table 1). Scores on the YMRS did not change
significantly throughout the study in both M and NM groups; the
two groups did not differ on the YMRS at any time-point through
the 12-month observation period, indicating the absence of signif-
icant manic/hypomanic symptomatology in patients with unipo-
lar or bipolar depression who were exposed to a full, 20-session
dTMS cycle.
The results of the present research suggest the possible utility
of add-on dTMS in patients with treatment-resistant depression
for both inducing antidepressant response and episode remis-
sion/recovery, and for obtaining relapse/recurrence prevention.
This approach, which integrates medications and dTMS, may
greatly impact the treatment of MDD and BD, as both disor-
ders are characterized by high rates of treatment-resistance and
relapse (21).
Since this was an add-on study, patients were concurrently
receiving constant doses of mood stabilizers and antidepressants
throughout the dTMS treatment period. The type of medications
varied widely, hence we cannot draw conclusions about the pos-
sible influence of any given drug on the antidepressant efficacy
elicited by dTMS; however, all these drugs and drug combinations
were ineffective at least for the last month before initiating dTMS.
We are not able to speculate with strong arguments about
the protective effect of maintenance dTMS against depressive
episodes and more so, against manic episodes. There is evidence
for other somatic treatments, like electroconvulsive therapy, as
inducers of manic switches in unipolar or bipolar patients with
depression (22); we may state that this problem did not emerge
with dTMS in our population, but since no patient presented sig-
nificant variations in YMRS scores in either M or NM groups, we
may not infer as to the value of maintenance dTMS in protect-
ing against manic episodes, but only remark the low propensity
of dTMS in the long run to associate with mood elevations.
Regarding a putative maintenance dTMS-mediated protection
from depressive mood episodes, we observed a decreased incidence
of relapses/recurrences in the M group compared to the NM group,
and also a not significant elevation of HRDS scores in the former
group, compared to significant elevations at both 6- and 12-month
follow-up in the NM group. However, the sample size was low and
it might have supported the creation of an artifact; in fact, sim-
ilar differences from an arbitrarily chosen second baseline (the
HDRS score at the completion of the regular cycle) did not yield
statistical significance for the M group at the 12-month follow-
up (9.83± 1.27 vs. 12.92± 5.78, p= 0.252) while they did for the
NM group at the 6-month follow-up (9.92± 2.35 vs. 13.75± 5.53,
p= 0.046). We may speculate that maintenance had a role in pre-
venting depressive episodes, but that there is a tendency for this
effect to be lost after some time. Studies using maintenance strate-
gies involving more continuous“recall”sessions (for example,once
a month or so) could inform us better about the potential of
maintenance dTMS to avoid the relapse/recurrence of depressive
episodes.
No serious adverse events occurred during the trial. Some
patients reported only mild and transient side effects such as nau-
sea, diaphoresis, mild headache, and scalp discomfort. This is con-
sistent with literature on the effects of dTMS on neuropsychiatric
disturbances (9, 23–26).
These data extend the antidepressant efficacy of add-on dTMS
that we obtained in the past in comorbid alcohol use disorder
and dysthymic disorder (18, 19) to major depression and BD. It
appears that resting left DLPFC perfusion is key indicator of later
antidepressant response to left DLPFC stimulation (27).
STUDY LIMITATIONS
The open design, the small sample size, a possible confounding
effect of add-on medication, the lack of a sham control, the popula-
tion heterogeneity, the two heterogeneous sites involved constitute
the major limitations of this preliminary study. Furthermore, we
excluded left handers on the grounds that we should change the
parameters of our device to stimulate the dominant hemisphere
in that population, and this was not currently feasible [or, alter-
natively, to decrease stimulus frequency below 1 Hz to account
for the proposed hemisphere imbalance in depression (5)]. Thus,
our results should be considered as preliminary. Nevertheless, they
point toward a new frontier in the long-term treatment of depres-
sive symptomatology, regardless of diagnostic category. Future
studies should use larger and more homogeneous samples with
double-blind designs and address problems related with handed-
ness to better assess the potential efficacy of dTMS in the treatment
and the prevention of depressive episodes in mood disorders.
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